Print Mode Enable Media Only

News chronological

4 items before 1151546 (Keyword: "foundayo" (~4 currently found))

THENATIONALPULSE (Pulse Wires) - Medicare Launches New Weight Loss Drug Pipeline.

Medicare's first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost.

Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity . PULSE POINTS WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously,…Open

AXIOS (Tina Reed) - Medicare weight-loss drug coverage could overwhelm doctors

Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices. The big picture: It could become one of the biggest drug rollouts ever — and it could test an already burdened system as seniors seek new GLP-1 prescriptions. - Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects. - Medicare has been prohibited by law from covering weight-loss drugs. Where it stands: The new program is part of a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for…

NPR (Sydney Lupkin) - The FDA approves a new obesity pill, giving patients another option

The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form of Wegovy as an alternative to obesity drugs given by injection.